133 related articles for article (PubMed ID: 17034352)
1. Oxidative stress and therapeutic approaches in HIV dementia.
Steiner J; Haughey N; Li W; Venkatesan A; Anderson C; Reid R; Malpica T; Pocernich C; Butterfield DA; Nath A
Antioxid Redox Signal; 2006; 8(11-12):2089-100. PubMed ID: 17034352
[TBL] [Abstract][Full Text] [Related]
2. Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes.
Pocernich CB; Sultana R; Hone E; Turchan J; Martins RN; Calabrese V; Nath A; Butterfield DA
J Neurosci Res; 2004 Aug; 77(4):532-9. PubMed ID: 15264223
[TBL] [Abstract][Full Text] [Related]
3. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations.
Pocernich CB; Sultana R; Mohmmad-Abdul H; Nath A; Butterfield DA
Brain Res Brain Res Rev; 2005 Dec; 50(1):14-26. PubMed ID: 15890409
[TBL] [Abstract][Full Text] [Related]
4. Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl.
Turchan-Cholewo J; Liu Y; Gartner S; Reid R; Jie C; Peng X; Chen KC; Chauhan A; Haughey N; Cutler R; Mattson MP; Pardo C; Conant K; Sacktor N; McArthur JC; Hauser KF; Gairola C; Nath A
Neurobiol Dis; 2006 Jul; 23(1):109-19. PubMed ID: 16697650
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants.
Turchan J; Pocernich CB; Gairola C; Chauhan A; Schifitto G; Butterfield DA; Buch S; Narayan O; Sinai A; Geiger J; Berger JR; Elford H; Nath A
Neurology; 2003 Jan; 60(2):307-14. PubMed ID: 12552050
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective therapy for HIV dementia.
Turchan J; Sacktor N; Wojna V; Conant K; Nath A
Curr HIV Res; 2003 Oct; 1(4):373-83. PubMed ID: 15049424
[TBL] [Abstract][Full Text] [Related]
7. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.
Bjugstad KB; Flitter WD; Garland WA; Philpot RM; Kirstein CL; Arendash GW
J Neurovirol; 2000 Dec; 6(6):478-91. PubMed ID: 11175320
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants.
Mollace V; Nottet HS; Clayette P; Turco MC; Muscoli C; Salvemini D; Perno CF
Trends Neurosci; 2001 Jul; 24(7):411-6. PubMed ID: 11410272
[TBL] [Abstract][Full Text] [Related]
9. Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment.
Sacktor N; Miyahara S; Evans S; Schifitto G; Cohen B; Haughey N; Drewes JL; Graham D; Zink MC; Anderson C; Nath A; Pardo CA; McCarthy S; Hosey L; Clifford D;
J Neurovirol; 2014 Dec; 20(6):620-6. PubMed ID: 25377444
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological frontiers in the treatment of AIDS dementia.
McGuire D; Marder K
J Psychopharmacol; 2000; 14(3):251-7. PubMed ID: 11106304
[TBL] [Abstract][Full Text] [Related]
11. Lost in translation: again, another failed neuroprotection trial.
Brew BJ
Neurology; 2007 Sep; 69(13):1308-9. PubMed ID: 17893290
[No Abstract] [Full Text] [Related]
12. Cell death in HIV dementia.
Mattson MP; Haughey NJ; Nath A
Cell Death Differ; 2005 Aug; 12 Suppl 1():893-904. PubMed ID: 15761472
[TBL] [Abstract][Full Text] [Related]
13. Associative and predictive biomarkers of dementia in HIV-1-infected patients.
Bandaru VV; McArthur JC; Sacktor N; Cutler RG; Knapp EL; Mattson MP; Haughey NJ
Neurology; 2007 May; 68(18):1481-7. PubMed ID: 17470750
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 infection and cognitive impairment in the cART era: a review.
Schouten J; Cinque P; Gisslen M; Reiss P; Portegies P
AIDS; 2011 Mar; 25(5):561-75. PubMed ID: 21160410
[TBL] [Abstract][Full Text] [Related]
15. Evolving paradigms in the pathogenesis of HIV-1-associated dementia.
Fischer-Smith T; Rappaport J
Expert Rev Mol Med; 2005 Dec; 7(27):1-26. PubMed ID: 16321172
[TBL] [Abstract][Full Text] [Related]
16. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
Schifitto G; Zhang J; Evans SR; Sacktor N; Simpson D; Millar LL; Hung VL; Miller EN; Smith E; Ellis RJ; Valcour V; Singer E; Marra CM; Kolson D; Weihe J; Remmel R; Katzenstein D; Clifford DB;
Neurology; 2007 Sep; 69(13):1314-21. PubMed ID: 17652642
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective strategies for HIV-1 associated dementia.
Dou H; Kingsley JD; Mosley RL; Gelbard HA; Gendelman HE
Neurotox Res; 2004; 6(7-8):503-21. PubMed ID: 15639783
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection in HIV-positive drug users: implications for antioxidant therapy.
Shor-Posner G; Lecusay R; Morales G; Campa A; Miguez-Burbano MJ
J Acquir Immune Defic Syndr; 2002 Oct; 31 Suppl 2():S84-8. PubMed ID: 12394787
[TBL] [Abstract][Full Text] [Related]
19. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort.
Valcour V; Shikuma C; Shiramizu B; Watters M; Poff P; Selnes OA; Grove J; Liu Y; Abdul-Majid KB; Gartner S; Sacktor N
J Neuroimmunol; 2004 Dec; 157(1-2):197-202. PubMed ID: 15579298
[TBL] [Abstract][Full Text] [Related]
20. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments.
Gray F; Adle-Biassette H; Chretien F; Lorin de la Grandmaison G; Force G; Keohane C
Clin Neuropathol; 2001; 20(4):146-55. PubMed ID: 11495003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
